Success Metrics

Clinical Success Rate

100.0%

Based on 1 completed trials

Completion Rate

100%(1/1)

Active Trials

0(0%)

Results Posted

100%(1 trials)

Phase Distribution

Ph phase_3

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution2 total trials

Phase 3Large-scale testing

2(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(1)

Terminated(1)

Detailed Status

Withdrawn1

Completed1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 32 (100.0%)

Trials by Status

withdrawn150%

completed150%

Recent Activity

0 active trials

Showing 2 of 2

completedphase_3

A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

NCT02924688

withdrawnphase_3

Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled Asthma

NCT03376932

Clinical Trials (2)

Showing 2 of 2 trials

NCT02924688Phase 3

A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

Completed

NCT03376932Phase 3

Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled Asthma

Withdrawn

All 2 trials loaded

Drug Details

Intervention Type: DEVICE
Total Trials: 2